جست‌وجوی استاد و پژوهشگر

Theresa Raimondoمشاهده پروفایل

استادیار

• Biomaterials
• Drug Delivery
• RNA-based Therapeutics
• +۵ مورد دیگر

Theresa Raimondo is the Manning Assistant Professor of Engineering at Brown University, with a secondary appointment in the Division of Biology and Medicine. She joined the Brown Engineering faculty in January 2024 after completing her postdoctoral training at MIT's Koch Institute. Dr. Raimondo leads the Raimondo Research Lab, which focuses on chemically modifying RNA and designing nanoparticles for therapeutic delivery to the body, an immunotherapy concept that holds immense promise in the field of immunoengineering. Her educational background includes: PhD in Engineering Sciences – Bioengineering from Harvard University (2019) MEng from Harvard University (2019) Sc.B. in Chemical and Biochemical Engineering from Brown University (2011) Dr. Raimondo's research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her work primarily centers on developing novel lipid nanoparticles (LNPs) for RNA-based therapies, contributing to adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By optimizing LNP formulation and modulating RNA constructs, she seeks to understand how RNA-LNPs modulate immunity and develop new therapeutic approaches. Her expertise spans biomaterials, drug delivery, biomolecular engineering, nanomedicine, tissue engineering, and regenerative medicine. Analysis of Dr. Raimondo's recent publications reveals a strong focus on RNA delivery systems and lipid nanoparticle technology. Her work spans from fundamental studies on nanoparticle design to applications in cancer immunotherapy, vaccine development, and tissue regeneration. A significant portion of her research involves optimizing lipid formulations for improved mRNA delivery and exploring how these systems interact with the immune system. Her publications demonstrate a trajectory from basic biomaterials research to increasingly translational work with therapeutic applications. Dr. Raimondo has received numerous prestigious awards: 2025 NAE Symposium selection (Grainger Foundation Frontiers of Engineering) 2025 appointment to the inaugural Early Career Board of ACS Applied Bio Materials 2024 selection as MIT Faculty Founder Initiative finalist 2022 Convergence Scholar fellowship from MIT's Marble Center for Cancer Nanomedicine National Science Foundation graduate research fellowship Harvard's Smith family graduate fellowship Dr. Raimondo is actively involved in mentoring students through courses including ENGN 0931L - Biomedical Engineering Design and Innovation II, ENGN 1490 - Biomaterials, and ENGN 1931L - Biomedical Engineering Design and Innovation II. Her research program is supported by various grants, though specific funding sources aren't detailed in the provided text. The Raimondo Research Lab represents a dynamic environment where engineering principles are applied to solve complex biological challenges in drug delivery and regenerative medicine. The Raimondo Research Lab at Brown University serves as a hub for innovation in RNA delivery and biomaterials design. The lab brings together expertise in chemical engineering, molecular biology, and immunology to develop next-generation therapeutic platforms. Current research directions include optimizing lipid nanoparticle formulations, exploring novel RNA modifications, and investigating immune responses to RNA therapeutics across various disease contexts.

Tobias Dickمشاهده پروفایل

استاد

• Redox Biology
• Signal Transduction
• Cellular Physiology
• +۳ مورد دیگر

Tobias Dick serves as Professor and Head of the Division of Redox Regulation at the German Cancer Research Center (DKFZ) in Heidelberg, maintaining a primary affiliation with Heidelberg University's Faculty of Biosciences. His leadership spans molecular switch research within the SFB/TRR186 consortium focusing on spatio-temporal control of cellular signal transmission. Academic Background: PhD in Biochemistry, Freie Universität Berlin (1997, summa cum laude) Habilitation in Biochemistry, Heidelberg University (2009) Diploma thesis at German Cancer Research Center (1994) Study program in Biochemistry, Freie Universität Berlin (1989-1994) Research Focus: Dick pioneers investigations into thiol-based redox switches governing cellular signal transduction. His work establishes fundamental mechanisms of peroxiredoxin-mediated hydrogen peroxide signaling, protein persulfidation dynamics, and sulfur-based radical scavenging systems. Key contributions include developing real-time imaging probes for redox species and elucidating redox relays connecting peroxiredoxins to transcription factors like STAT3. Current research explores hydropersulfide protection against ferroptosis and metabolic adaptation through redox-sensitive enzymes. Publication Trends: Over 15 years of high-impact publications reveal an evolutionary trajectory from foundational redox imaging techniques (2008-2011) to sophisticated molecular mechanism studies (2013-2020), culminating in recent breakthroughs on sulfur signaling in cell death pathways (2023). His work consistently appears in premier journals like Nature Chemical Biology , demonstrating sustained innovation in redox biology methodology and conceptual frameworks. Scientific Recognition: ERC Advanced Grant (2017) Society for Free Radical Research Europe Basic Science Award (2017) Chica- and Heinz-Schaller-Award for young scientists (2009) Marie Curie Excellence Grant (2004) DFG Postdoctoral Fellowship (1998-2000) Studienstiftung des Deutschen Volkes Scholarship (1989-1994) Leadership & Mentorship: As founding vice-coordinator of DFG priority program SPP1710 (2014-present) and GBM Redox Biology Study Group (2011-2017), Dick shapes national research agendas. His division at DKFZ mentors next-generation scientists through ERC and DFG-funded projects, with trainees contributing to landmark publications on redox switches and cellular physiology. Research Infrastructure: The Division of Redox Regulation operates within DKFZ's state-of-the-art facilities, collaborating extensively through the SFB/TRR186 consortium. This environment enables cutting-edge investigations into redox-controlled cellular processes using advanced biochemical, imaging, and computational approaches.

Audrey Lambمشاهده پروفایل

استاد

• Mechanistic enzymology
• Metabolic pathways
• Structural biology
• +۴ مورد دیگر

Dr. Audrey Lamb is a Professor and Chair of the Department of Chemistry at The University of Texas at San Antonio (UTSA), within the College of Sciences. She joined UTSA in 2020 after rising to full professor at the University of Kansas, where she served as interim dean of graduate studies in 2019. Her leadership extends to professional organizations, including serving as an elected council member for the American Society for Biochemistry and Molecular Biology. Dr. Lamb received her B.S. in Chemistry from Furman University in 1993 and her Ph.D. in Biochemistry from Vanderbilt University School of Medicine in 1998. She completed postdoctoral studies in biochemistry at Northwestern University before beginning her academic career at the University of Kansas in 2003. Dr. Lamb's research focuses on understanding bacterial pathogenesis through mechanistic enzymology and structural biology. Her lab investigates how human pathogens biosynthesize metallophores for metal ion scavenging and riboflavin (Vitamin B2) biosynthesis pathways. These studies aim to identify targets for novel antibiotic development against multidrug-resistant pathogens. Her work spans bacterial enzymology, structural biology, and metabolic pathway analysis, with applications in antimicrobial drug design. Analysis of Dr. Lamb's recent publications reveals a consistent focus on enzyme mechanisms in bacterial metabolism, particularly in metallophore and riboflavin biosynthesis pathways. Her work combines structural biology with kinetic analysis to elucidate catalytic mechanisms. Many publications investigate enzymes from pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, and Trypanosoma cruzi, highlighting the translational potential of her basic science research for antimicrobial development. Dr. Lamb has received notable recognition including: Election as a 2022 Fellow of the American Association for the Advancement of Science (AAAS) Award-winning teaching and mentoring at undergraduate and graduate levels Dr. Lamb has mentored numerous students and postdoctoral fellows, with many alumni now in academic, industrial, and research positions. Her lab has received funding from prestigious sources including the National Institutes of Health, National Science Foundation, American Lung Association, and W.M. Keck Foundation. She actively collaborates with researchers at Loyola University Chicago, Texas A&M University, University of Kansas Medical Center, and UTSA's Department of Molecular Microbiology and Immunology. The Lamb Lab maintains a comprehensive suite of equipment for protein biochemistry and structural studies, including multiple AKTA FPLCs, a stopped-flow spectrophotometer, crystallization robot, various spectrophotometers, and HPLCs. This infrastructure supports their research on enzyme mechanisms and structural biology of bacterial metabolic pathways.

• Cancer Immunology
• Innate Lymphoid Cells
• Regulatory T Cells
• +۵ مورد دیگر

Dr. Tim Halim is a Sir Henry Dale Fellow and Junior Group Leader at the Cancer Research UK Cambridge Institute (CRUK Cambridge Institute), University of Cambridge. His primary research program focuses on pancreatic cancer, with thoracic cancer as a secondary research focus within the CRUK Cambridge Centre's structured research programs. Dr. Halim's research expertise lies at the intersection of cancer biology and immunology, with particular emphasis on innate lymphoid cells (especially ILC2) and regulatory T cells within the tumor microenvironment. His work investigates how these immune cell populations interact with cancer cells and influence tumor progression, metastasis, and response to therapy. His research has significant implications for developing novel immunotherapeutic approaches for pancreatic and thoracic cancers. His publication record demonstrates a consistent focus on the role of innate lymphoid cells in cancer, with recent work examining IL-33 and ILC2 in pancreatic cancer, cross-talk between ILC2 and regulatory T cells, and the influence of innate lymphoid cells on pancreatic stromal composition. His research employs advanced techniques including in vivo labeling, single-cell analysis, and fate-mapping approaches to understand immune cell behavior in cancer contexts. Dr. Halim has been awarded the prestigious Sir Henry Dale Fellowship, a joint fellowship from the Royal Society and Wellcome Trust that supports early-career researchers of outstanding promise working at the interface of basic and clinical science.

Hong Hanمشاهده پروفایل

استادیار

• Cancer Biology
• Gene Regulation
• RNA Splicing
• +۵ مورد دیگر

Hong Han is an Assistant Professor in the Department of Biochemistry & Biomedical Sciences within McMaster University's Faculty of Health Sciences and a member of the Centre for Discovery in Cancer Research (CDCR). She holds a Canada Research Chair and leads the Han Lab, which focuses on cancer biology, RNA regulation, and innovative high-throughput technologies for therapeutic discovery. Dr. Han earned her Ph.D. from the University of Toronto (2010-2016) and has established herself as a leading researcher in glioblastoma and alternative splicing regulation. Her interdisciplinary research integrates cancer biology, RNA science, and multilayer gene regulation to uncover mechanisms underlying cancer progression and treatment resistance. Her laboratory pioneers integrated technological platforms for large-scale genetic/drug screening and ultra-high-throughput single-cell profiling. The research focuses on three main areas: alternative splicing regulation in cancer (particularly glioblastoma and prostate cancer), multilayer mechanisms of glioblastoma heterogeneity and microenvironment evolution, and multiplexed screening approaches for therapeutic discovery in treatment-resistant cancers. Analysis of Dr. Han's recent publications reveals a strong emphasis on single-cell technologies to characterize glioblastoma heterogeneity, minimal residual disease states, and tumor-immune interactions. Her work increasingly bridges basic RNA biology with translational applications, particularly in developing novel therapeutic strategies targeting splicing networks and immune evasion mechanisms. Canada Research Chair Dr. Han teaches Advanced Techniques in the Biomedical Sciences (BIOCHEM 734). Her research program is supported by multiple funding sources, as evidenced by her extensive publication record in high-impact journals including Nature, Cell, Molecular Cell, and Nature Communications. She employs a comprehensive approach combining in vitro, in vivo, and patient cohort studies with cutting-edge genomic technologies. The Han Lab has developed innovative multiplexed screening platforms that enable simultaneous interrogation of thousands of conditions, ranging from CAR-T cells to small molecule therapeutics. This approach accelerates the discovery of novel cancer targets and therapeutic strategies for treatment-resistant cancers.

Joshua D. Rabinowitzمشاهده پروفایل

استاد

• Cellular Metabolism
• Metabolomics
• Systems Biology
• +۵ مورد دیگر

Joshua D. Rabinowitz is a Professor of Chemistry and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where he also serves as Director of the Ludwig Princeton Branch. His research focuses on achieving a quantitative, comprehensive understanding of cellular metabolism, with applications in both basic science and medical research. Dr. Rabinowitz's research interests span multiple areas of metabolism and systems biology: Quantitative analysis of metabolic networks and regulation Metabolomics and measurement of metabolite concentrations and fluxes Cancer cell metabolism and therapeutic targeting Metabolic regulation in microbes (E. coli, Saccharomyces cerevisiae) Biofuel production (focusing on Clostridium acetobutylicum) Metabolic impact of pathogen infection (viral infection of human cells) His laboratory has developed innovative methods for measuring cellular metabolites using state-of-the-art mass spectrometry technology and approaches for quantitating metabolic fluxes through isotope-labeling data interpretation. Analysis of recent publications reveals a strong focus on NAD+ metabolism, cancer metabolism, metabolic adaptations in disease states, and the intersection of metabolism with immunology and neuroscience, particularly in areas like T cell metabolism, Alzheimer's disease, and cardiac function. Dr. Rabinowitz has received recognition as a Highly Cited Researcher by Web of Science, indicating significant impact in his field. He advises several graduate students and has mentored numerous alumni, including Michel I. Nofal, Edmundo Leiva III, and Sean Hackett. His research is supported by multiple programs including NIH NHGRI Training Program and QCB Graduate Program. The Rabinowitz Lab operates at the intersection of chemistry, biology, and computational science, with all projects involving a mix of biological experiments, metabolomics, and computation to achieve their goal of a holistic understanding of cellular metabolism.

David Junckerمشاهده پروفایل

استاد

• Microfluidics
• Nanotechnology
• Lab-on-a-Chip
• +۶ مورد دیگر

David Juncker is a Professor and Department Chair of the Department of Biomedical Engineering at McGill University. He serves as a Principal Investigator at the McGill University & Genome Quebec Innovation Centre and holds associate memberships in the Department of Neurology and Neurosurgery, Department of Electrical and Computer Engineering, Division of Experimental Medicine, Department of Surgery, and Goodman Cancer Research Centre. His research focuses on micro- and nano-bioengineering technologies for bioanalysis, precision medicine, and organs-on-chips. Key areas include microfluidics, lab-on-a-chip devices, biomedical sensors, medical diagnostics, biomaterials, tissue engineering, and cancer biomarker discovery. His lab develops scalable antibody microarrays, self-powered diagnostic platforms, microfluidic probes for brain tissue perfusion, and nanogradients for neuronal navigation, with applications in cancer diagnostics, global health, and neuroscience. Recent publications (2023-2025) reveal strong emphasis on extracellular vesicle analysis, single-cell proteomics, 3D-printed microfluidic/organ-on-a-chip systems, and capillary-driven circuits. Key trends include low-cost point-of-care diagnostics, advanced circulating tumor cell isolation methods, and biomimetic synthetic vesicles for drug delivery, demonstrating translational potential in early disease detection. Dr. Juncker leads a highly interdisciplinary team comprising undergraduate and graduate students, post-doctoral fellows, and staff from diverse scientific, engineering, and cultural backgrounds. His lab actively recruits Canadian/permanent resident graduate students for projects on single extracellular vesicle and protein detection in cancer and infectious diseases, leveraging microfluidics and wearables for biomarker discovery. The Juncker Lab operates from the McGill University & Genome Quebec Innovation Centre (740 Dr. Penfield Avenue, Room 6206). It maintains a collaborative, multicultural environment focused on developing transformative micro- and nano-bioengineering technologies with significant potential impact on human health diagnostics and treatment.

Gustavo M. Silvaمشاهده پروفایل

دانشیار

• Molecular Biology
• Cell Biology
• Ubiquitin Signaling
• +۴ مورد دیگر

Gustavo M. Silva is the Jack H. Neely Associate Professor of Biology at Duke University's Trinity College of Arts & Sciences, a position he has held since 2025. Previously, he served as Associate Professor of Biology (2024-present) and Assistant Professor of Cell Biology (2022-present) at Duke. His research is conducted through the Silva Lab (sites.duke.edu/silvalab), which focuses on molecular mechanisms of cellular stress response. Education: Ph.D. from University of Sao Paulo (Brazil), 2010 B.Sc. from University of Sao Paulo (Brazil), 2004 Dr. Silva's research centers on understanding how gene expression is regulated at transcriptional and translational levels during cellular stress. His lab specifically investigates how the ubiquitin system controls protein synthesis and degradation dynamics under stress conditions, which are critical for cellular physiology. His work has significant implications for understanding disease mechanisms where protein homeostasis is disrupted. The research combines biochemical, genetic, and proteomic approaches to dissect these complex regulatory networks. His publication record demonstrates a clear evolution from fundamental studies on redox regulation and proteasome function to more complex investigations of ubiquitin signaling in translation control and stress response. Recent work increasingly focuses on K63-linked ubiquitination's role in ribosome function and translation regulation, with growing emphasis on the clinical implications of these mechanisms in disease contexts including cancer. Scientific Awards & Recognition: Paul T. Englund Emerging Scholar Award (Johns Hopkins School of Medicine, 2024) Dean's Award for Excellence in Mentoring (Duke Graduate School, 2023) Science Diversity Leadership Award (Chan Zuckerberg Initiative, 2022) Best Professor Award (Vanderbilt Basic Sciences Juneteenth Committee, 2022) 100 inspiring Black scientists in America (CellPress, 2020) Dr. Silva actively mentors students at multiple levels, as evidenced by his Dean's Award for Excellence in Mentoring. His research is supported by substantial funding including NIH grants such as the Tri-Institutional Molecular Mycology and Pathogenesis Training Program (2024-2029) and 'Stalling cancer at the ribosome' from the V Foundation for Cancer Research (2025-2028). He also serves as Principal Investigator on multiple R01 grants focused on ubiquitin's role in translation control and stress response. The Silva Lab maintains strong collaborative relationships with institutions including the Chan Zuckerberg Initiative and ETH Zurich, and participates in several interdisciplinary training programs at Duke that support underrepresented students in biomedical sciences.

Cecilia Lealمشاهده پروفایل

استاد

• Soft Condensed Matter
• Biomaterials
• Drug Delivery
• +۵ مورد دیگر

Cecilia Leal is a Professor and Racheff Faculty Scholar in the Department of Materials Science and Engineering at the University of Illinois at Urbana-Champaign, with additional appointments at the Carle Illinois College of Medicine, Materials Research Laboratory, and Beckman Institute. Her interdisciplinary research program bridges materials science, biophysics, and medicine to develop innovative therapeutic delivery systems. Dr. Leal's research focuses on the self-organization of biomolecular systems, particularly lipid membranes, peptides, and nucleic acids. Her lab investigates how structural complexity of lipids and bio-membranes relates to disease mechanisms and informs the design of better gene and drug delivery systems. Key projects include developing lipid nanoparticles for mRNA delivery, studying polymer-lipid hybrid membranes, and characterizing lipid droplet dynamics in metabolic diseases. The lab employs advanced techniques including Small Angle X-ray Scattering, Cryo-EM, and live cell imaging. Her recent publications (2023-2025) reveal a strong emphasis on lipid-based delivery systems for mRNA therapeutics and cancer treatment, with particular attention to how nanostructure affects delivery efficiency. The research spans from fundamental biophysics of lipid-polymer interactions to applied therapeutic development, demonstrating consistent translation of basic science to medical applications. University of Illinois Provost's Distinguished Promotion to Full Professor Award (2024) University of Illinois Scholar (2023) NIH New Innovator Award (2016) NSF CAREER Award (2016) Racheff Faculty Scholar Award (2019) Dr. Leal has mentored numerous graduate students and postdocs, many now in prominent positions at MIT, Stanford, Dow Chemical, and pharmaceutical companies. Her research is supported by multiple NIH and NSF grants, and she maintains active collaborations with medical researchers studying obesity, cancer, and respiratory diseases. She teaches core courses including MSE 201 (Phases and Phase Relations) and MSE 473 (Biomolecular Materials Science), consistently earning excellent teaching ratings. The Leal Lab operates as an interdisciplinary team of materials scientists, physicists, and chemists using cutting-edge characterization tools to solve biomedical challenges. The lab's work on lipid nanoparticle structure has direct relevance to next-generation mRNA vaccines and cancer therapies, with several publications highlighted in C&EN News and other prominent scientific media.

• Cancer Genomics
• Precision Medicine
• Colorectal Cancer Research
• +۵ مورد دیگر

Tobias Sjöblom serves as Professor and Head of Department at Uppsala University's Department of Immunology, Genetics and Pathology, where he leads the Cancer Precision Medicine research program. His work bridges clinical oncology and molecular biology, with particular focus on translating genomic findings into clinical applications for cancer patients. His research interests center on cancer genomics, precision medicine, and molecular diagnostics, with extensive work on colorectal cancer biology and treatment. Sjöblom's laboratory investigates how genetic variations influence cancer development, progression, and response to therapy, particularly focusing on pharmacogenomic biomarkers that can guide personalized treatment decisions. His work spans from basic molecular mechanisms to clinical applications, with strong emphasis on translating research findings into clinical practice. Analyzing his recent publication record reveals a clear trajectory toward precision oncology applications, with increasing focus on liquid biopsy technologies, AI-assisted diagnostics, and biomarker-driven treatment strategies. His research demonstrates a consistent pattern of investigating how specific genetic alterations (particularly in NAT2, CYP2D6, and other metabolic enzymes) can be leveraged for targeted cancer therapies. The interdisciplinary nature of his work is evident in collaborations spanning molecular biology, clinical oncology, bioinformatics, and medical imaging. Sjöblom has established significant research infrastructure through initiatives like the U-CAN biobank, creating valuable resources for cancer research across Sweden. His leadership extends to developing novel methodologies for cancer genomics and diagnostics, including advanced techniques for mutation detection and tissue analysis. His laboratory maintains strong clinical connections, working closely with oncologists and surgeons to ensure research questions address real clinical challenges. This translational approach has resulted in numerous publications in high-impact journals including Nature, Science, and Cell Death and Disease, demonstrating the significance and quality of his contributions to cancer research.

John Diffleyمشاهده پروفایل

استاد

• DNA Replication
• Cell Cycle Control
• Chromosome Biology
• +۵ مورد دیگر

John Diffley is a Principal Group Leader and Associate Research Director at The Francis Crick Institute in London, UK, where he leads research on DNA replication mechanisms. His work focuses on understanding how cells precisely duplicate their DNA during cell division and how errors in this process contribute to cancer development. Diffley obtained his PhD from New York University in 1985 and completed postdoctoral training with Bruce Stillman at Cold Spring Harbor Laboratory until 1990. He established his research group at the Clare Hall Laboratories (originally Imperial Cancer Research Fund, then Cancer Research UK) before moving to The Francis Crick Institute in 2015. His research spans DNA replication initiation, cell cycle control, replication fork checkpoints, and epigenetic inheritance. Diffley's lab has pioneered methods to reconstitute chromatin replication using purified proteins, providing unprecedented insights into chromosome biology. His team combines genetics, cell biology, and biochemistry to study the molecular 'machines' that copy DNA in yeast and human cells. Analysis of Diffley's recent publications reveals a strong focus on structural mechanisms of DNA replication, particularly using cryo-EM to visualize replication machinery. His work examines helicase loading and activation, replication fork stability under stress, and the connection between replication errors and cancer development. The research spans model organisms to human cells, with increasing emphasis on structural approaches in recent years. FRS (Fellow of the Royal Society) FMedSci (Fellow of the Academy of Medical Sciences) Diffley actively mentors a diverse team of postdoctoral researchers and PhD students, investigating various aspects of DNA replication. His lab has received substantial funding to support their work on replication mechanisms, with projects spanning basic biochemical reconstitution to studies of replication errors in cancer contexts. The lab maintains multiple technical platforms including structural biology, biochemistry, and cell biology approaches. His research group operates within The Francis Crick Institute's collaborative environment, utilizing shared facilities for structural biology, microscopy, and genomics to advance understanding of DNA replication mechanisms and their implications for genome stability and disease.

Jeffrey Beekmanمشاهده پروفایل

استاد

• Cystic Fibrosis
• Regenerative Medicine
• Stem Cell Research
• +۵ مورد دیگر

Jeffrey Beekman is a Full Professor at the University Medical Center Utrecht, specializing in translational research for chronic diseases through the Department of Pediatric Pulmonology. His work bridges basic and clinical research to develop novel diagnostics and therapeutics for conditions like cystic fibrosis (CF) and Primary Ciliary Dyskinesia. Education: PhD in Molecular Immunology (2004) Key Roles: Principle Investigator since 2010, co-founder of FAIR Therapeutics, Board Member of the Dutch Society for Stem Cell Research His research focuses on patient-derived organoid models to study disease mechanisms, validate therapeutic targets, and optimize drug development. Strategic programs include Child Health and Regenerative Medicine & Stem Cells . Recent publications highlight his work on CFTR gene therapy, organoid-based drug efficacy testing, and host-pathogen interactions in CF. Collaborations span molecular biology, clinical pulmonology, and biotech translation. Key Techniques: Organoid modeling, RNA sequencing, Forskolin-induced swelling assay Diseases Studied: Cystic Fibrosis, Colorectal Cancer Susceptibility, Primary Ciliary Dyskinesia

Ananya Choudhuryمشاهده پروفایل

استاد

• Radiation Therapy
• Prostate Cancer
• Bladder Cancer
• +۹ مورد دیگر

Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.

• Apoptosis
• Biochemistry
• Breast Neoplasms
• +۵ مورد دیگر

Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.

• Glycodrugs
• Protein-carbohydrate interactions
• Multivalency
• +۷ مورد دیگر

Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.